We are live on ! Find out more
PRDS

Pardes Biosciences, Inc. Common Stock
PRDS

Delisted

PRDS was delisted on the 30th of August, 2023.

Back to rankings

69 hedge funds and large institutions have $174M invested in Pardes Biosciences, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

1% less capital invested

Capital invested by funds: $176M → $174M (-$1.72M)

8% less funds holding

Funds holding: 75 → 69 (-6)

46% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 13

50% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 12

Holders
69
Holders Change
-6
Holders Change %
-8%
% of All Funds
1.2%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.07%
New
7
Increased
6
Reduced
12
Closed
13
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ACA
Arena Capital Advisors
California
+$11.9M
2
6CM
683 Capital Management
New York
+$2.01M
3
PMAM
Picton Mahoney Asset Management
Ontario, Canada
+$1M
4
LC
Littlejohn & Co
Connecticut
+$782K
5
SC
Sculptor Capital
New York
+$723K

Top Sellers

Rank Fund Capital Flow
1
GCL
Glazer Capital LLC
New York
-$4.35M
2
HM
HealthCor Management
New York
-$3.49M
3
Citadel Advisors
Citadel Advisors
Florida
-$2.48M
4
WRBC
W.R. Berkley Corp
Connecticut
-$1.78M
5
LGM
Logos Global Management
California
-$1.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
26
EcoR1 Capital
California
$1.5M – – –
SCM
27
Shaolin Capital Management
Florida
$1.25M +$49.9K +4,972 +4%
CCM
28
Context Capital Management
California
$1.25M +$251K +24,997 +25%
LGM
29
Logos Global Management
California
$1.23M -$1.77M -176,457 -59%
Marshall Wace
30
Marshall Wace
United Kingdom
$1.2M -$14.5K -1,440 -1%
Balyasny Asset Management
31
Balyasny Asset Management
Illinois
$1.2M – – –
CH
32
CVI Holdings
Delaware
$1M – – –
ACM
33
Altai Capital Management
California
$998K – – –
GL
34
Governors Lane
New York
$998K – – –
LOAMU
35
Lombard Odier Asset Management (USA)
New York
$998K – – –
PMAM
36
Picton Mahoney Asset Management
Ontario, Canada
$998K +$1M +100,000 New
LC
37
Littlejohn & Co
Connecticut
$779K +$782K +77,925 New
HF
38
HRT Financial
New York
$705K – – –
MAM
39
Melqart Asset Management
United Kingdom
$649K -$70.3K -7,000 -10%
AA
40
AQR Arbitrage
Connecticut
$500K – – –
Nomura Holdings
41
Nomura Holdings
Japan
$499K – – –
PSAMP
42
P. Schoenfeld Asset Management (PSAM)
New York
$499K – – –
RCM
43
Radcliffe Capital Management
Pennsylvania
$499K – – –
DKCM
44
Davidson Kempner Capital Management
New York
$498K – – –
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$472K +$474K +47,200 New
PC
46
Periscope Capital
Ontario, Canada
$458K -$195K -19,427 -30%
Susquehanna International Group
47
Susquehanna International Group
Pennsylvania
$442K – – –
TD Asset Management
48
TD Asset Management
Ontario, Canada
$439K – – –
HP
49
Hound Partners
New York
$348K -$933 -93 -0.3%
DAM
50
Deltec Asset Management
New York
$249K – – –
1
2
3 4

PRDS Hedge Fund Activity: Q2 2021 in Review

69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Pardes Biosciences, Inc. Common Stock (PRDS) for Q2 2021, worth a combined $174M — down 0.98% from $176M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of PRDS and 7 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 6 added.

The largest buyer was Arena Capital Advisors, adding an estimated $11.9M. The largest seller was Glazer Capital LLC, cutting an estimated $4.35M.

  • 69 institutional investors held Pardes Biosciences, Inc. Common Stock (PRDS) as of Q2 2021, down from 75 in Q1 2021.
  • Funds reported $174M of Pardes Biosciences, Inc. Common Stock stock for Q2 2021, down 0.98% quarter-over-quarter.
  • 7 funds opened new Pardes Biosciences, Inc. Common Stock positions in Q2 2021 and 13 closed out, a net change of -6 holders.
  • The largest Pardes Biosciences, Inc. Common Stock buyer in Q2 2021 was Arena Capital Advisors, an estimated $11.9M added.
  • The largest Pardes Biosciences, Inc. Common Stock seller in Q2 2021 was Glazer Capital LLC, an estimated $4.35M sold.

Based on aggregated 13F filings for Q2 2021.